Physician profile
Adaugo Sanyi
NPI 1205465366
$514.91
in general payments reported to CMS, 2019-2025
12 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.63 · 2023: $44.95 · 2024: $217 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.29 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $121.41 | 2024 | Tremfya |
| Pfizer INC. | $66.92 | 2024-2025 | |
| Abbvie INC. | $57.28 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $55.39 | 2023-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $43.22 | 2025 | Zoryve |
| Genzyme Corporation | $33.13 | 2025 | |
| Dermavant Sciences, INC. | $29.68 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $29.05 | 2025 | Sotyktu |
| Krystal Biotech INC | $25.44 | 2025 | Vyjuvek |
| Galderma Laboratories, L.P. | $18.63 | 2022 | |
| Janssen Scientific Affairs, LLC | $18.02 | 2025 | Tremfya |
| Lilly USA, LLC | $16.74 | 2024 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adaugo Sanyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.